The case report and palliative management of a patient with carcinoid syndrome and crises

Journal of Palliative Medicine

Volumn 12, Issue 8, 2009, Pages 743-745

  McPherson, Alan ^a   Regan, Joan ^a   Jackson, Neil ^b  

^a Somerton House ^*  (United Kingdom)

^b NORTHERN IRELAND HOSPICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; INTERFERON; OCTREOTIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARCINOID CRISIS; CARCINOID SYNDROME; CASE REPORT; CHEMOEMBOLIZATION; CONTINUOUS INFUSION; DETERIORATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; LIVER METASTASIS; WEIGHT REDUCTION;

FATAL OUTCOME; FEMALE; HUMANS; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; PALLIATIVE CARE; SEVERITY OF ILLNESS INDEX;

EID: 69249084952     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.0068     Document Type: Article

References (14)

1. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet 1998;352:799-805.
2. Battershill PE, Clissold SP: Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38:658-702.
3. Kvols LK, Maples WJ, O'Connell MJ (eds): Gastrointestinal Apudomas. London: Royal Society of Medicine Services Limited, 1988.
4. van der Horst-Schrivers AN, Wymenga AN, Links TP, Willemse PH, Kema IP, de Vries EG: Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology 2004;80(Suppl 1):28-32.
5. Van Gompel JJ, Sippel RS, Warner TF, Chen H: Gastrointestinal carcinoid tumors: Factors that predict outcome. World J Surg 2004;28:387-392.
6. Pasieka JL, McKinnon JG, Kinnear S, Yelle CA, Numerow L, Paterson A, Rorstad O, DiFrancesco LM, McEwan A, Skogseid B: Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: Symposium summary. Can J Surg 2001;44:25-32.
7. Lips CJ, Lentjes EG, Hoppener JW: The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem 2003;40(Pt 6):612-627.
8. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-973.
9. Jahng AW, Liao SS: Successful palliation with octreotide of a neuroendocrine syndrome from malignant melanoma. J Pain Symptom Manage 2006;32:191-195.
10. Anthony LB, Winn SD, Johnson DH, Hande KR, Oatres JA: Chronic "high-dose" octreotide in neuroendocrine neoplasms. Ann Oncol 1994;5(Suppl 5):139.
11. Deguchi H, Deguchi K, Tsukada T, Murashima S, Iwasaki E, Tsuda M, Kobayashi T, Shirakawa S: Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. Intern Med 1994;33:100-102.
12. Fox DJ, Khattar RS: Carcinoid heart disease: Presentation, diagnosis, and management. Heart 2004;90:1224-1228.
13. Williams MD, Dolenc TJ: Selective serotonin reuptake inhibitors and patients with carcinoid tumor. Psychosomatics 2005;46:370-372.
14. Simbera Z, Balon R: Carcinoid tumor, selective serotonin reuptake inhibitors, and diarrhea. Psychosomatics 2005;46:88-89.